News | January 11, 2024
Lupin launches Varenicline Tablets in US
Varenicline Tablets (RLD Chantix) had estimated annual sales of US $412 million in the US
Varenicline Tablets (RLD Chantix) had estimated annual sales of US $412 million in the US
CB03 is a candidate drug for the treatment of ALS and other central nerve system (CNS) diseases
Suven Life Sciences completed enrollment of patients to the phase-2, PoC clinical study of samelisant (SUVN-G3031) for the treatment of narcolepsy with or without cataplexy in USA and Canada
The partnership will capitalize on the combined capabilities of the two organizations
Envelta is the company’s non-opioid pain product candidate for acute and chronic pain
Brexpiprazole Tablets, 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, and 4 mg, (RLD Rexulti) had estimated annual sales of US $1,575 million in the US (IQVIA MAT December 2022)
The approved product is indicated for the treatment of adult patients with Multiple myeloma, in combination with Dexamethasone
The EIR was issued post the last inspection of the facility conducted from October 17, 2022 to October 29, 2022
The approval for Glycopyrrolate clears the path for more internally manufactured injectable products
With the recent sales force expansion and new product launches, we expect to be back to above-market growth
Subscribe To Our Newsletter & Stay Updated
